ITC Stock Analysis 2026: Value Opportunity or Recovery Trap?

Meet ITC: familiar brands, concentrated profits

ITC Limited is a diversified Indian company. It sells cigarettes and everyday consumer goods, sources and trades agricultural products, makes paperboards and packaging, and provides IT services through ITC Infotech. Familiar consumer brands include Aashirvaad, Sunfeast, Bingo!, YiPPee!, Classmate and Savlon. Company business overview; FY2026 annual report.

The important distinction is between sales and profits. In FY2026, cigarettes supplied roughly 40% of external net product sales but about 79% of segment EBITDA before corporate costs and eliminations. Consumer brands provide growth opportunities, yet the cigarette franchise still drives much of the valuation. Following the hotel demerger, ITC Hotels is an associate investment, not the old consolidated hotel operating segment. See the business and accounting bridge.

Recent share performance: a rebound within a weaker month

The latest available pre-market comparison is ₹266.20 for 17 September 2026. The published price-history series shows a 0.78% rise from ₹264.15 on 16 September, but a 2.51% decline from ₹273.05 on 17 August. It is 5.27% below ₹281.00 on 31 July. These are point-to-point price changes, not dividend-inclusive total returns, and are not evidence that the stock must rebound. Price-history source, checked 18 September 2026.

Our question is therefore not simply “has the share fallen?” It is whether the cash ITC can generate under reasonable recovery assumptions justifies the price paid. The cockpit summarises the answer; the sections below expose what must go right and what could go wrong.

How to read the ranges before acting

Think of each simulation as one internally calculated “what if” business path. We draw economic growth, cigarette recovery, margins and required return from stated ranges, calculate ten years of cash flow, then discount that cash into a value per share. The same 5,000 saved paths power the tables and charts. No inputs were changed for this reader update.

What must hold: the main simulation assumes FMCG reaches ₹50,000 crore by FY2031, cigarette volumes regain the prior-year run-rate in the second half of FY2027, and no extra near-term tobacco-tax shock. It also fixes working-capital days, terminal growth and terminal returns. Those conditions are not “proven” by 5,000 runs. If they fail, revalue the business rather than reuse the old add/reduce bands.

Lower entry prices offer more room for error; higher entry prices require more favourable outcomes. That is the reason for the staged-add and reduce framework. A falling share price is not itself confirmation of value, and a rising share price is not proof that the assumptions improved. The separate ₹206 stress combines weaker operating assumptions with a higher required return. It has no assigned probability.

The answer in one minute

Financial interest: the analyst holds ITC shares as a long-term investment; relatives may also hold shares. Read the dated disclosures before using this report.

At the verified publisher quote of ₹266.20, ITC looks inexpensive if cigarette earnings recover and FMCG delivers the assumed growth. The indicative central value is ₹382; the 5,000-run median is ₹370. That is a valuation case, not a promise that the market will agree.

Quote: 17 Sep 2026, 15:57 IST, Upstox; corroborated by Stock Analysis. Not independently certified as the exchange closing price. Values use an explicitly estimated September date bridge, not an observed September balance sheet. Report charge ₹0. [S17] [S18] [S19] [S32]

When to add, hold or reduce

A margin of safety is the discount you demand to an estimated value. If you estimate a business at ₹100 and pay ₹80, the margin is 20%. It is a cushion against mistakes, not insurance against loss.

At ₹266.20, the quote is in the staged-add band and 28.1% below the median. Yet the combined downside of ₹206 is 22.7% below the quote. Price alone is insufficient.

When: review after each quarterly result, any tobacco-tax change, material acquisition or capital-allocation announcement. Add only if retained realization, volume recovery and cash conversion support the forecast. If evidence weakens, reduce the valuation first; do not average down simply because the price fell.

Research horizon: 3-5 years, not a dated price target. Reference benchmark for later performance review: Nifty 50 Total Return Index; relative outperformance is not modelled. Consult a SEBI-registered investment adviser/qualified financial adviser for suitability, diversification, taxes and position sizing. These are general conditional rules, not individualized trade orders.

How entry price changes the model’s odds

At ₹266.20, 99.5% of draws exceed the quote, but only 77.1% support a 20% safety margin. At ₹450 the corresponding figures are 11.7% and 0.1%. These high/low frequencies are caused by the assumed model, not independently established likelihoods.

Formula: frequency = qualifying trials / 5,000. A 20% cushion requires model value ≥ entry price / 0.80. Neither column measures future market prices, total returns, drawdown or the probability of beating the benchmark.

5,000 scenarios, not 5,000 promises

The middle half of the September outcomes is ₹336-₹413; the central 90% spans ₹296-₹486. The model fixes FMCG target achievement, mid-FY27 cigarette volume run-rate recovery and no additional near-term tobacco tax shock.

More runs reduce random sampling noise; they do not make optimistic assumptions true. Even a 100% simulated frequency is not certainty. Around a 50% event, 5,000 independent draws have about ±1.4 percentage points of Monte Carlo sampling error at a rough 95% level, before the much larger uncertainty about the model itself.

Where the economics come from

ITC combines high-profit cigarette operations with growing consumer brands, agricultural sourcing and trading, paper and packaging, and services. Consolidated cigarette results include Surya Nepal. “Others” includes ITC Infotech, the retained Grand Central hotel and fresh food. Demerged ITC Hotels is an associate, not the former consolidated hotel operating segment. [S1]

Diversification is a revenue fact, but cigarette economics still dominate segment profit. Faster growth in a lower-margin business can dilute the group margin even when each business improves. Tobacco taxation, illicit substitution and public-health regulation therefore remain central risks, not footnotes.

India’s FMCG opportunity: large, but not all ITC’s

FMCG means everyday packaged consumer goods: food, personal care and household products. A growing market helps, but ITC still has to win shelf space, repeat purchases and profitable market share.

Do not divide the ₹24,315 crore revenue number by the dollar market estimate and call the answer ITC’s market share. Currency, calendar year, geography, category coverage and retail-versus-company-sales definitions differ. Neither the industry estimate nor the 2035 opportunity is independently used as a growth multiplier.

₹50,000 crore is a reported medium-term aspiration; FY31 is our assumed deadline. Achieving it is already built into every main simulation. The lower-target rows are separate tests with other central assumptions unchanged, not assigned probabilities. [S8] [S32]

Where ITC leads, and where shares are undisclosed

The FY26 annual report attributes category standing to Nielsen and Kantar Household Panel. It provides ranks, not current market-share percentages for every category. “Not disclosed” below means missing public evidence; it does not mean zero market share. [S1]

All these categories sit within the FMCG forecast; no separate category-share forecast is added on top. A defensible percentage-share model requires licensed category data with matching year, value/volume measure, geography and organized/unorganized denominator. Current public reports do not support a complete numerical share map. [S1] [S21]

Higher income does not mechanically mean more smoking

Affordability cost = percentage of annual GDP per person needed for 2,000 cigarettes of the most-sold brand, WHO 2024. Higher means less affordable. It uses GDP, not the GNI column, and predates India’s 2026 tax changes. Prevalence measures people who smoke, not sticks per smoker or company volumes.

India’s low cigarette prevalence is not empty demand waiting to be filled: bidis and smokeless tobacco, health awareness, affordability, gender differences and regulation matter. Income growth can support premium products, but country comparisons do not prove causality or a future conversion rate to cigarettes. No five-country correlation is used to calibrate ITC growth.

Tax shocks: recovery is possible, full recovery is not automatic

These examples are not a random sample of independent events. Inventory stocking, illicit trade, inflation, income, other tobacco controls and product substitution confound the results. They inform stress tests; they do not establish the probability that ITC recovers by a particular quarter.

Can ITC keep raising cigarette prices?

There are three prices to distinguish: what the smoker pays, what ITC retains after taxes and trade margins, and what the investor pays for the share. A tax hike may lift the first, reduce the second and hurt the third.

Distribution: beta-PERT minimum 2%, most-likely 5%, maximum 7%; selected once per trial, then growth fades later. Positive pricing occurs in 100% of these draws because negative growth was excluded by assumption. These are not empirical probabilities that ITC will deliver such pricing. The 85% retained-price recovery assumption is a separate catch-up, not another ordinary annual price rise. [S32]

Calculated as (1+price change)^elasticity – 1, holding income and other factors fixed. WHO’s broad evidence often puts consumption loss near 4-5% for a 10% price rise. Our wider sensitivity is judgment, not an ITC-specific estimate. Do not apply retail-price elasticities directly to a net-of-tax revenue shock. [S33]

Model consequence: keep the main simulation conditional, but test normal retained pricing of only 2%, no catch-up and weaker volume together. A real probability of pricing success would require consistent ITC volume/realization data, tax-adjusted prices and a fitted, out-of-sample tested demand model. Public cross-country averages are insufficient.

History informs recovery; it does not guarantee it

Margins above are segment results plus D&A, using net cigarette revenue and total segment revenue for the other businesses. FY22-FY23 include the pre-demerger hotel perimeter; FY24 uses later-restated continuing figures. The series is not perfectly constant-perimeter. [S1] [S2] [S3] [S4] [S5]

The denominator matters. Cigarette gross revenue includes ₹8,520.36 crore of revenue taxes; the model removes them to derive net sales. Agri and paper profits include internal trading, which must be considered when applying segment margins but eliminated from consolidated sales. This correction removes the earlier denominator mismatch. [S1]

Screener’s historical operating-profit proxy and revenue presentation are not identical to this bridge. Its historical margins cannot be pasted onto this denominator. A complete vendor-to-annual-report line-item bridge remains outstanding; this report uses the audited segment definition consistently. [S10]

Management: implementation is stronger evidence than aspiration

Q1 FY27: management describes staggered cigarette pricing and product interventions, with consolidated FMCG revenue up 15% and group EBITDA down 24% year on year. These observations support adaptation, but neither proves a quantified cigarette recovery schedule. [S6]

The ₹50,000 crore FMCG topline aspiration was reported as medium-term. FY2031 is our model convention, not a verified deadline. It is company revenue, not consumer spending or the addressable market. The distinction materially affects forecast credibility. [S8]

The chairman’s ₹20,000 crore medium-term capex plan is treated as a five-year floor in the model. That timing is an analytical choice, not precise annual guidance. [S7]

Research notebook: what we learned and changed

This is an edited, public-facing digest of the dated research record, not a verbatim internal working log. It records evidence, corrections, decisions and unresolved tests. Earlier checkpoints are superseded where identified; their figures must not be combined with the current valuation. The underlying annual-report references remain available in Sources.

Management plans: progress, shortfalls and open tests

The FY2022–FY2026 Board/business and subsidiary reviews support the observations below. “Supported” means evidence of implementation, not that management beat formal numerical guidance. Most plans are qualitative. Company explanations are not independent causal proof; external cycles and reporting scope also matter. FY2026, FY2025, FY2024, FY2023, FY2022.

Next review checklist: compare disclosed cigarette volumes and retained realization with the recovery path; separate FMCG organic growth from acquisitions; track segment margins, leaf/wood costs, working-capital days and capex returns; record any tax, rainfall, export-policy or material transaction changes. Keep the previous assumption and date visible when revising a view. No numerical management score or historical “hit rate” is inferred.

What actually drives forecast revenue?

FY32-FY36 growth fades toward 3.5%. Income per person is derived from GDP and population, so it is not an independent extra growth term. Cigarette volume responds by 0.25 percentage points for a one-point deviation in per-person growth from the centre: a judgment, not an estimated causal coefficient. [S10]

Operating leverage must be earned

A one-time tax-rate rise can permanently change the level of legal volumes or retained realization. “No further tax rise” does not imply full recovery. The central case grants recovery but leaves failure possible in the retained-price range.

Q1 FY27 actual EBITDA is ₹5,181 crore on ₹18,955 crore net product/service revenue (27.33%). The remaining nine months require 26.78% on the same basis, rather than an abrupt 35% full-year margin. Full-year group margin of 26.69% uses a slightly broader revenue denominator. [S9] [S10]

Growth consumes cash before it creates value

Formula: operating WC = sales × DSO/365 + materials cost × (DIO-DPO)/365 + other operating WC. FCFF = EBIT × (1-tax) + D&A – organic capex – lease investment – organic ΔWC – acquisition cash. [S10]

Ten years of sales, earnings and cash flow

FY26-FY36 revenue CAGR is 8.22%; continuing EPS CAGR is 7.64%. EPS falls in FY27 then recovers. Flat treasury income, financing, associates, minorities and dilution explain why EPS does not exactly track sales or EBITDA. These are estimates, not audited future financial statements. [S10]

FY27 group revenue grows only about 1% despite faster FMCG and acquired paper capacity. Cigarette net revenue contracts about 21%. The initial earnings-level loss is not removed by calling the tax increase “one-off”; the model must earn it back through subsequent pricing, volumes and cost normalization. [S10]

The original DCF: a transparent starting point

Formula: enterprise value = Σ FCFFt/(1+r)^t + terminal FCFF/[(r-g) × (1+r)^10]. Equity value = enterprise value + net non-operating bridge. Divide by diluted shares. Year-end discounting is used. [S10]

Internal-trading weights are assumptions: 75% of Agri internal sales are linked to cigarette volume/input inflation and 25% to FMCG sales; paper uses 50%/50%. Corporate profit eliminations scale with internal turnover. These are not disclosed procurement shares. Other operating revenue grows 5% before fade; lease investment is about 0.081% of sales. [S10]

The next page rolls this starting point to the comparison date. The original bridge is not reclassified or marked to market merely because the report now includes a current share quote.

Bringing the valuation to today’s comparison date

The earlier ₹375.96 value used a 31 March base date. Comparing it with September without accounting for the ₹8 dividend already paid would be inconsistent. We now use an explicit, estimated stub-year bridge. It is a valuation timing update, not a fresh audited September balance sheet.

Method: spread recurring FY27 cash flow evenly across the year; assume the model’s ₹3,528cr acquisition cash is already spent; deduct the ₹8 final dividend paid 28 July 2026; shorten future discount periods by 171/365. Keep the remaining FY27 cash flow at year-end. Cash earns zero in this bridge. [S19] [S32]

Limitations: actual seasonality, acquisition payment schedules, share dilution, minority claims and investment market values are not fully refreshed. These can change the answer. A ₹5,000cr adverse change in the non-operating bridge reduces value by about ₹3.99/share. No precision beyond rounded rupees is economically warranted.

No double counting: elapsed operating cash is removed from future cash flows before being added to the bridge. The acquisition outflow and paid dividend are deducted once. The already-paid dividend is not included in potential future upside. The share quote does not enter any forecast assumption.

The discount rate is a judgment with a large price

The earlier conventional build used: (7.0167% sovereign yield – 1.7499% default spread) + 0.5132 beta × 4.20% mature equity premium + 2.7202% country equity premium ≈ 10.14% cost of equity. A 1% assumed debt weight, a 0.75% borrowing spread and corporate tax shield yield about 10.10% WACC. Revenue-weighted global industry betas are an imperfect proxy for business-value weights. [S11] [S12] [S10]

An FD yield plus an explicit equity premium is an investor hurdle, not automatically WACC. Deposit credit risk, tenor and tax treatment differ from perpetual equity. No particular “RBI tax-free bond” has been identified; the model must not invent its yield or tax status. The selected midpoint leaves only 1.56 percentage points above the saved sovereign reference. This may undercompensate equity risk.

Terminal cash flows represent about 66.1% of the date-adjusted operating value. In plain English, most of the valuation depends on cash earned beyond the ten-year forecast. The 10% discount-rate test values the share near ₹300, not ₹382.

What can break the attractive valuation?

The combined downside is 22.7% below today’s quote even before stronger margin, weather or funding stress. It is illustrative, not a worst case or a probability estimate. This is why a 99.5% favourable model frequency must never become “99.5% chance of investment success.”

Ranges and dependencies: the model’s contract

The shared profitability factor is beta-PERT on 0-1 with midpoint 0.5; segment endpoints are mapped piecewise around their central values. These margins have perfect rank dependence by construction. Other non-macro risk draws are independent. This is neither a fitted covariance model nor proof of causality. [S10]

Fixed conditions: FMCG reaches ₹50,000cr in FY31; Agri follows GDP before fade; terminal g 3.5%; terminal ROIC 15%; selected WC days and tax rate. No additional near-term tax shock is drawn. Later adverse tax events, target failure, future acquisition funding and multi-year weather regimes are not fully represented.

See the assumptions behind the simulation

Each bar shows the percentage of the 5,000 saved scenarios falling into that interval. The dashed line is the sample median. Low / central / high inputs are documented below and in the downloadable workbook. Open each image at full size for its labels; the numerical table supplies a text alternative. These are assumed distributions, not fitted forecasts.

Across years, GDP uses an assumed common latent factor with correlation 0.60. Per-capita growth equals (1 + GDP growth) / 1.01 − 1. Normal cigarette volume has a separate draw plus an income-response adjustment. The discount-rate draw is independent of operating draws. These links are modelling choices, not causal estimates. The ₹50,000 crore FMCG target, terminal growth of 3.5% and terminal ROIC of 15% are fixed, so no random-distribution chart is invented for them. Full ranges and dependencies.

What could invalidate the investment case?

These mechanisms are economic hypotheses, not established causal coefficients. Monsoon, inflation, demand and costs can move together. The current simulation does not capture all such joint downside states; it would be misleading to describe the bounded range as comprehensive. [S1] [S6] [S7] [S10]

Questions a retail investor should ask

Is ITC a buy at ₹266.20?

It is a conditional staged-add candidate in this framework, below the ₹269 safety band. That conclusion assumes the recovery case remains intact and is subject to individual suitability and adviser checks. It is not a universal recommendation for every investor.

What is the difference between value and return?

Value estimates what future business cash might be worth today. Return depends on your entry price, dividends received, future selling price, timing, taxes and costs. The model does not simulate the price at which you will actually sell.

What do DCF, EBITDA and terminal value mean?

DCF discounts future cash into today’s rupees. EBITDA is operating profit before interest, tax and depreciation; it is not free cash. Terminal value estimates the cash earned after the detailed forecast ends. Growing sales can consume cash through inventory and factories.

What does Benjamin Graham’s formula say?

The limited heuristic EPS × (8.5 + 2g), using normalized EPS ₹16.07 and separate EPS-growth input g=6, gives ₹329.44. It is not a date-aligned cash-flow target or independent proof. It cannot model tax shocks, reinvestment or changing business mix. [S10]

What will change the view?

Evidence of sustained cigarette volume/retained-realization recovery, FMCG organic growth and cash margins, or a different required return. Further taxes, poor monsoon transmission, expensive acquisitions or weaker cash conversion can lower value even if the stock falls.

Is the report free, and are trading costs included?

The report charge is ₹0. Brokerage, exchange/statutory charges and investor taxes are separate and are not included in the valuation gaps. Consult an adviser before acting; past business performance and model outcomes do not assure future returns.

Latest update — 18 September 2026

Reader update: added a company introduction and dated share-performance context, official ITC logo, clearer Research Cockpit, research-learning record and twelve assumption/output distributions across three charts. The safety-first summary now appears in the cockpit; the detailed price-band rationale remains below.

Valuation unchanged: central ₹382, median ₹370, P5–P95 ₹296–₹486; separate combined downside ₹206. This is a presentation and documentation update, not new quarterly results or a rerun with revised forecasts. The linked PDF is the original 18 September release edition; this expanded web edition adds the reader notes and assumption charts. The existing Excel companion remains the matching valuation audit file.

This section is the report’s update history. No later update has been published here yet. Future dated updates can be linked from this section and from the cockpit’s Latest update link. Check the date, changed assumptions and revised conclusion before relying on an older download.

Disclosures and publication status

Dated disclosures: 18 September 2026. Subject company: ITC Limited. Analyst: Aditya Siddharth Mehta, individual SEBI-registered Research Analyst, INH000029768; BSE enlistment 7462. Company Anatomy is the publication name. Report charge: ₹0.

Financial interests and ownership

The analyst holds ITC shares as a long-term investment. Relatives may also hold ITC shares as long-term investments. This financial interest can create a potential conflict. In response to the ownership question for 31 August 2026, the analyst states that, to his knowledge, no person within the queried analyst/associate/relative scope holds 1% or more. These are analyst declarations, not an independent holdings audit.

Compensation, relationships and conduct

The analyst declares no ITC-related compensation, including in the preceding 12 months. Apart from the disclosed holdings, he declares no ITC-related roles, service/client relationships, non-cash benefits, other material conflicts or relevant disciplinary matters involving himself or applicable associates. The declaration covers the queried officer/director/employee, market-making and public-offering relationships. He confirms compliance with the applicable personal-trading restriction under Regulation 16(2).

Analyst approval and AI assistance

The named analyst has approved the analytical views, conditional accumulation/holding/reduction framework and AI assistance, subject to the release-date price refresh, and retains responsibility for the published research. AI assisted data collection, analysis, calculations/code, readability, some writing and document production. The editorial illustration is AI-generated, not a photograph; numerical charts are calculated from the stated data. Errors may remain: readers should verify material information and perform their own due diligence. This warning does not displace the analyst’s responsibilities.

Risks and scope

This is general research, not personalized investment advice, a buy/sell solicitation, an offer, or an assurance of returns. It nevertheless contains conditional investment views. Consult a SEBI-registered investment adviser or qualified financial adviser on suitability, diversification, position sizing, taxes and costs. DCF values depend on assumptions; simulation frequencies are not probabilities of investment success. The report is free; brokerage, statutory charges and investor taxes are separate. Free public access does not itself create a personalized advisory engagement or waive regulatory protections.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, enlistment with BSE and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Contact, complaints and research limitations

Aditya Siddharth Mehta / Company Anatomy. Registered contact: Aditya Villa, Daksha Niwas, S.T. Road, Chembur, Mumbai, Maharashtra 400071. Email and grievance contact: adi2001me@gmail.com. Telephone: +91 7021135925. Registration and contact particulars are reproduced from the website disclosures reviewed on 17 September 2026.

Raise a complaint with the analyst first. If unresolved, use SEBI SCORES (https://scores.sebi.gov.in/) and, where applicable, SMART ODR (https://smartodr.in/). Website terms, disclosures, Investor Charter and complaint information remain applicable: https://companyanatomy.com/disclosures-disclaimers/ ; https://companyanatomy.com/investor-charter/ ; https://companyanatomy.com/grievance-redressal/ .

Release scope: price and valuation timing refreshed on 18 September 2026 before market opening, using the latest available 17 September quote. Operating evidence and forecast assumptions remain those of the 16 September analytical checkpoint. Cash/investment values and share count are carried-forward estimates, not newly observed September accounts. Changes after the information cut-off may invalidate the analysis. No undertaking to update continuously is made.

The 5,000-scenario companion contains frozen operating forecasts with live valuation formulas. The separately dated 500-trial source model is retained for operating-formula inspection and is not an updated price comparison. Neither file was newly executed in native Microsoft Excel. Statistical outputs are conditional model results, not forecasts of future traded prices.

Figures and tables are original analytical presentations of attributed facts. Third-party annual reports and research publications remain the property of their respective owners and are linked, not republished as website downloads. Distribution is intended only where lawful. Refer to the dated original report for corrections and revisions.

Sources and data notes 1

[S1] ITC Report and Accounts 2026
Consolidated revenue Note 19, p271; tax presentation p298; segment note pp299-300; Board business reviews. Audited results and classifications. Local report re-read 16 Sep 2026. Open source

[S2] ITC Report and Accounts 2025
Consolidated revenue p274, segment note pp305-306, Board/subsidiary reviews. Includes restated FY24 continuing comparisons. Open source

[S3] ITC Report and Accounts 2024
Board review and segment note pp318-320; FY24 numerical comparisons use the FY25 restatement where available. Open source

[S4] ITC Report and Accounts 2023
Board reviews pp45-46, revenue p277, segment note pp300-301. Pre-demerger scope for FY22-FY23. Open source

[S5] ITC Report and Accounts 2022
Board/business reviews pp44-45; revenue p276 and segment note pp298-299. Historical recovery context, not a forward guidance source. Open source

[S6] ITC Q1 FY2027 results media statement
31 July 2026. Consolidated and standalone highlights are separately labelled. Staggered pricing and weather/input/trade risks. Rechecked 16 Sep 2026. Open source

[S7] ITC chairman’s 115th AGM address
23 July 2026. Medium-term capex and business strategy. Company commentary is not independent verification of causal claims. Open source

Sources and data notes 2

[S8] Business Standard: Sanjiv Puri at Manthan 2026
24 February 2026. Secondary reporting of the ₹50,000 crore medium-term FMCG topline aspiration. Does not establish an FY2031 deadline. Open source

[S9] ITC Q1 FY2027 results presentation
Page 29, rounded consolidated figures: ₹18,955cr net products/services revenue and ₹5,181cr EBITDA. Saved model source; online full-PDF retrieval timed out during report preparation. Open source

[S10] Company Anatomy working model and calculation archive
ITC_DCF_Recovery_2026-09-16.xlsx: Controls, Ten Year Forecast, Costs and EPS, Simulation, Simulation Trials. 500 formula trials plus central replay. Independent saved-file verification; native desktop Excel recalculation not tested. Forecasts are author judgments. Open source

[S11] CCIL tenor-wise indicative sovereign yields
Model uses the saved 11 September 2026 9-10-year YTM of 7.0167%, not the latest website observation. Dated-source reproduction and commercial-use permission require publisher review. Open source

[S12] Aswath Damodaran, NYU Stern risk datasets
July 2026 country-risk dataset and global industry beta methodology inform the earlier conventional WACC reference. Country-risk and beta assumptions are not current ITC market-implied inputs. Open source

[S13] SEBI Research Analysts Regulations, 2014
Consolidated text last amended 25 November 2025; Regulations 19-22, pp17-19. Covers disclosures, AI use, report basis and distribution. Official copy saved and read. Open source

[S14] SEBI Master Circular for Research Analysts
6 February 2026, section 11, pp33-37: advertising and brand-name provisions. Official copy saved and read. Applicability and later RAASB directions require release review. Open source

Sources and data notes 3

[S15] Google Search Central: AI features
SEO fundamentals, crawlability, visible text and matching metadata support discoverability. Inclusion and ranking are not guaranteed. Publisher implementation reference. Open source

[S16] Google Search Central: Article structured data
Article metadata should match visible author/content and real publication details. No invented author credentials or publication URL. Publisher implementation reference. Open source

[S17] Upstox ITC quote
17 Sep 2026 15:57 IST: ₹266.20. Latest available before the 18 Sep market open; publisher quote, not independently certified exchange close. Open source

[S18] Stock Analysis ITC price history
Daily price history corroborates ₹266.20 for 17 Sep 2026. Retrieved 18 Sep before market opening. Open source

[S19] ITC shareholder general information
Final dividend ₹8/share paid 28 Jul 2026, record date 27 May. Used once in the date bridge. Open source

[S20] IBEF Indian retail industry analysis
May 2026 industry page: broad Indian FMCG market US$288bn in 2025. An industry estimate; definitions differ from company revenue. Open source

[S21] ITC Q3 FY25 results FAQ
Category ranks on printed page 9. Historical corroboration only; FY26 annual report p49 is preferred for current core ranks. Open source

Sources and data notes 4

[S22] World Bank national-income data
GNI per capita, Atlas method, current US$, 2024; indicator NY.GNP.PCAP.CD. API data saved; downloaded 16 Sep 2026. GNI is not median household disposable income. Open source

[S23] WHO tobacco profile: India
2025 report, pp2 and 8: harmonized 2023 current cigarette smoking, both sexes 15+, age-standardized; 2024 affordability. Official PDF archived. Open source

[S24] WHO tobacco profile: Indonesia
2025 report, pp2 and 8: harmonized 2023 current cigarette smoking, both sexes 15+, age-standardized; 2024 affordability. Official PDF archived. Open source

[S25] WHO tobacco profile: China
2025 report, pp2 and 8: harmonized 2023 current cigarette smoking, both sexes 15+, age-standardized; 2024 affordability. Official PDF archived. Open source

[S26] WHO tobacco profile: Republic of Korea
2025 report, pp2 and 8: harmonized 2023 current cigarette smoking, both sexes 15+, age-standardized; 2024 affordability. Official PDF archived. Open source

[S27] WHO tobacco profile: United States
2025 report, pp2 and 8: harmonized 2023 current cigarette smoking, both sexes 15+, age-standardized; 2024 affordability. Official PDF archived. Open source

[S28] World Bank: tobacco tax reform in Korea
2018 policy report, discussion of 2015 reform and incomplete rebound. Price hike 80%; stockpiling cautions and sales/tax measurement limits. Open source

Sources and data notes 5

[S29] Korea National Tobacco Control Center
Ministry of Economy and Finance sales series: 2014 4.36bn packs, 2015 3.33, 2016 3.66, 2017 3.44, 2018 3.14, 2019 3.21, 2020 3.06, 2021 3.15, 2022 3.09. Open source

[S30] WHO China tax-increase assessment
10 May 2016: retail prices up about 10%, cigarette sales down 3.3% Apr15-Mar16 vs prior year; concurrent policies also changed. Open source

[S31] Philippines Department of Health / WHO FCTC
January 2024 presentation, p8: current tobacco-smoking prevalence (not cigarette-only), GATS 2009/2015/2021. Used as a policy-sequence example, not a matched country cross-section. Open source

[S32] Company Anatomy 5,000-trial valuation companion
Seed 2026091601, original 500 independently replayed; full draw and annual-output files supplied. Live valuation formulas on frozen operating cash flows. Native Excel execution not newly tested. Open source

[S33] WHO: health taxes and consumption evidence
Eastern Mediterranean Health Journal 2024 review. Broad price-response evidence, not an ITC elasticity or pricing-success estimate. Open source

[S34] ITC FY2015 results statement
Company account of repeated excise increases and legal-market pressure. Stakeholder commentary, not an independent estimate of illicit activity or causality. Open source